Please wait while we load the requested 10-Q report or click the link below:
https://last10k.com/sec-filings/report/899866/000089986619000099/alxn930201910q.htm
July 2021
July 2021
May 2021
May 2021
April 2021
March 2021
February 2021
February 2021
January 2021
December 2020
• | 3Q19 total revenues of $1,263.1 million, a 23 percent increase over 3Q18 and a 23 percent volume increase |
• | 3Q19 GAAP diluted EPS of $2.08; non-GAAP diluted EPS of $2.79 |
• | Received 2 recent regulatory approvals - ULTOMIRIS® (ravulizumab-cwvz) for atypical hemolytic uremic syndrome (aHUS) in the U.S. and SOLIRIS® (eculizumab) for adults with neuromyelitis optica spectrum disorder (NMOSD) in the EU |
• | Announced agreement to acquire Achillion Pharmaceuticals |
• | Continued disciplined business development execution with Eidos and Stealth BioTherapeutics collaborations |
• | Increased revenues and EPS guidance to reflect strong business and continued growth |
• | Total net product sales were $1,263.1 million in the third quarter of 2019, compared to $1,026.5 million in the third quarter of 2018. |
Please wait while we load the requested 10-Q report or click the link below:
https://last10k.com/sec-filings/report/899866/000089986619000099/alxn930201910q.htm
Compare this 10-Q Quarterly Report to its predecessor by reading our highlights to see what text and tables were removed , added and changed by Alexion Pharmaceuticals, Inc..
Alexion Pharmaceuticals, Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2019 10-K Annual Report includes:
Rating
Learn More![]()
49 During the third quarter 2019, the U.S. patent term extension to a composition of matter patent for STRENSIQ was granted, which resulted in a change in the estimated useful life of the STRENSIQ intangible asset and will result in lower amortization expense in future periods.Change in Fair Value of Contingent ConsiderationFor the three and nine months ended September 30, 2019, the expense resulting from the change in fair value of contingent consideration associated with our prior business combinations was $29.8 and $7.2, respectively, as compared to $53.5 and $110.9 for the three and nine months ended September 30, 2018.
Generalized Myasthenia Gravis (gMG) Myasthenia Gravis (MG) is a debilitating, complement-mediated neuromuscular disease in which patients suffer profound muscle weakness throughout the body, resulting in slurred speech, impaired swallowing and choking, double vision, upper and lower extremity weakness, disabling fatigue, shortness of breath due to respiratory muscle weakness and episodes of respiratory failure.
We expect increases in cash flows from operations, which will be highly dependent on sales levels and the related cash collections from sales of our products.
Selling, General and Administrative Expense 2019 Selling General and Administrative Expense (SG&A) 2018 Selling General and Administrative Expense (SG&A) SG&A as a % of net product sales 48 Our selling, general and administrative expense includes commercial and administrative personnel, corporate facility and external costs required to support the marketing and sales of our commercialized products.
Partially offset by the following: Decrease of $10.4 in product development expenses primarily related to a decrease in costs associated with milestone expenses.
We anticipate that cash generated...Read more
The increase in cash used...Read more
Income Taxes 2019 Income Tax...Read more
50 Other Income and (Expense)...Read more
52 Financial Condition, Liquidity and...Read more
However, readers should carefully review...Read more
Partially offsetting these increases was...Read more
Amortization of Purchase Intangible Assets...Read more
These tax benefits decreased the...Read more
As of October 21, 2019,...Read more
To date, we have not...Read more
The increase in cash used...Read more
This increase was offset by...Read more
In January 2019 we paid...Read more
Accordingly, the value of the...Read more
The increase in cash was...Read more
The income tax expense for...Read more
The remaining change in the...Read more
On October 22, 2019, the...Read more
Clinical development costs are comprised...Read more
The agreement with Affibody was...Read more
Alexion's acquisition of Achillion is...Read more
These selling, general and administrative...Read more
The nine months ended September...Read more
The deferred tax benefits include...Read more
Other R&D expenses consist of...Read more
Excluding the impact of any...Read more
The agreement also provides for...Read more
Increase in external selling, general...Read more
This increase in unit volumes...Read more
We operate in certain jurisdictions...Read more
The increase was primarily related...Read more
43 Net Product Sales Net...Read more
Increase of $14.6 in payroll...Read more
Increase of $27.6 in payroll...Read more
Acquired In-Process Research and Development...Read more
Under the terms of the...Read more
To the extent CFC earnings...Read more
We cannot guarantee that results...Read more
We believe the judgments, estimates...Read more
Financial Statements, Disclosures and Schedules
Inside this 10-Q Quarterly Report
Material Contracts, Statements, Certifications & more
Alexion Pharmaceuticals, Inc. provided additional information to their SEC Filing as exhibits
Ticker: ALXN
CIK: 899866
Form Type: 10-Q Quarterly Report
Accession Number: 0000899866-19-000099
Submitted to the SEC: Wed Oct 23 2019 3:56:30 AM EST
Accepted by the SEC: Wed Oct 23 2019
Period: Monday, September 30, 2019
Industry: Pharmaceutical Preparations